This study aims to provide 12-year nationwide epidemiology data to investigate the epidemiology and comorbidities of and therapeutic options for chronic fatigue syndrome (CFS) by analyzing the National Health Insurance Research Database.
Methods
6306 patients identified as having CFS during the 2000–2012 period and 6306 controls (with similar distributions of age and sex) were analyzed.
Result
The patients with CFS were predominantly female and aged 35–64 years in Taiwan and presented a higher proportion of depression, anxiety disorder, insomnia, Crohn’s disease, ulcerative colitis, renal disease, type 2 diabetes, gout, dyslipidemia, rheumatoid arthritis, Sjogren syndrome, and herpes zoster. The use of selective serotonin receptor inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), Serotonin antagonist and reuptake inhibitors (SARIs), Tricyclic antidepressants (TCAs), benzodiazepine (BZD), Norepinephrine-dopamine reuptake inhibitors (NDRIs), muscle relaxants, analgesic drugs, psychotherapies, and exercise therapies was prescribed significantly more frequently in the CFS cohort than in the control group.
Conclusion
This large national study shared the mainstream therapies of CFS in Taiwan, we noticed these treatments reported effective to relieve symptoms in previous studies. Furthermore, our findings indicate that clinicians should have a heightened awareness of the comorbidities of CFS, especially in psychiatric problems.
Hinweise
Kam-Hang Leong, Hei-Tung Yip and Chien-Feng Kuo are joint first authors and contributed equally to this paper
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Introduction
Chronic fatigue syndrome (CFS), also known as myalgic encephalomyelitis, is characterized by the experience of debilitating fatigue for more than 6 months that is not improved by rest [1]. The World Health Organization classifies CFS as a neurological illness, and over the last 30 years, numerous studies have identified and verified the diagnostic criteria for CFS, which are unexplained persistent or relapsing fatigue lasting at least 6 months with the addition of the concurrent presence of four or more of the following symptoms over a 6-month period: unusual postexertion fatigue, impaired memory or concentration, unrefreshing sleep, headache, muscle pain, joint pain, sore throat, and tender cervical nodes [2].
Several studies have indicated that the following multifactorial mechanisms contribute to the onset of CFS: Epstein–Barr virus, human herpes virus 6 [3], Helicobacter pylori,[4] Mycobacterium tuberculosis infection [5], immunoinflammatory pathways [6], neuroimmune dysfunctions [7], and oxidative and nitrosative stress pathways, such as those induced by burn injury [8, 9]. It also shares some features of autoimmune disease. In addition, we previously reported that inflammatory bowel disease, herpes zoster and psoriasis are associated with an increased risk of subsequent CFS [10‐12].
Anzeige
CFS considerably reduces patients’ quality of life and places a financial burden on the patients, their families, and health care systems [13]. The primary goals of management are to relieve symptoms and provide supportive health care to improve functional capacities. However, no pharmaceutical therapies have been licensed for CFS nor has any strong evidence been revealed on the efficacy of a single regimen. In the present study, we investigated the epidemiology and comorbidities of and therapeutic options for CFS by using Taiwan’s National Health Insurance Research Database (NHIRD). Our results can help physicians diagnose CFS early and manage the disorder effectively.
Methods
Data source
The data set used in this study was derived from the NHIRD, which contains details concerning the demographic characteristics, dates of admission and discharge, drug prescriptions, surgical procedures, and diagnostic codes for approximately 99% of Taiwan’s population of 23 million. The 2000 Longitudinal Health Insurance Database, which is a data subset of the NHIRD, includes all the original claims data and registration files for 1 million individuals randomly sampled from among the beneficiaries of the NHI program in 2000 in Taiwan. The diseases are defined according to the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM).
Sample participants
Cases of CFS were identified using two outpatient records or one admission record with a diagnosis of ICD-9-CM code 780.71. The date of the first diagnosis of CFS was the index date. For each CFS case, we used a frequency matching method to select a participant without CFS with the same sex, age, and index date as a control. Participants aged below 18 years or with missing information on sex were excluded.
Exposure assessment and comorbidities
For this study, we examined exposure to pharmaceutical and nonpharmaceutical treatments. In terms of exposure to pharmaceutical treatments, we included the following: selective serotonin receptor inhibitors (SSRIs) (Anatomical Therapeutic Chemical (ATC) code N06AB10, N06AB06, N06AB03, N06AB08 and N06AB05), serotonin norepinephrine reuptake inhibitors (SNRIs) (ATC code N06AX21 and N06AX16), Serotonin antagonist and reuptake inhibitors (SARIs) (ATC code N06AX05), Tricyclic antidepressants (TCAs) (ATC code N06AA09 and N06CA01), benzodiazepine (BZD) (ATC code N03AE01, N05BA06, N05BA12, N05BA01, N05BA17, N05BA22, N05CD04, N05CD05, N05CD03, N05CD09, N05CD01 and N05CD08), Norepinephrine-dopamine reuptake inhibitors (NDRIs) (ATC code N06AX12), Noradrenergic and specific serotonergic antidepressants (NaSSAs) (ATC code N06AX11), muscle relaxants (ATC code M03BX08), and analgesic drugs (including acetaminophen, nonsteroidal anti-inflammatory drugs [NSAIDs], pregabalin, and gabapentin) (ATC code M02AA, D11AX18, M01A, M01B, N03AX16, and N03AX12). With regard to nonpharmaceutical treatments, we included supportive individual psychotherapy, supportive group psychotherapy, intensive individual psychotherapy, intensive group psychotherapy, reeducative individual psychotherapy, reeducative group psychotherapy, behavior modification assessments, behavior modification planning, stretching exercise, therapeutic exercise, breathing exercises, reconditioning exercise, multiple physical examinations of sleep, brainwave examination, sleep or wakefulness and a brainwave examination for sleep disorders. We made adjustments for the potentially confounding effects of other comorbidities, including depression(ICD-9-CM code 296.2, 296.3, 926.82, 300.4, 309.0, 309.1, and 311), anxiety disorder (ICD-9-CM code 300.0–300.3, 300.5–300.9, 309.2–309.4, 309.81, and 313.0), Insomnia (ICD-9-CM code 307.41, 307.42, 780.50, and 780.52), suicide (ICD-9-CM code E950-E959), crohn's disease (ICD-9-CM code 555), ulcerative colitis (ICD-9-CM code 555–556), renal disease (ICD-9-CM code 580–589), diabetes mellitus (ICD-9-CM code 250 and A181), obesity (ICD-9-CM code 278), gout (ICD-9-CM code 274), dyslipidemia (ICD-9-CM code 272), malignancy (ICD-9-CM code 140–208), HIV (ICD-9-CM code 042–044), rheumatoid arthritis (ICD-9-CM code 714), psoriasis (ICD-9-CM code 696.x), ankylosing spondylitis (ICD-9-CM code 720.0), lymphadenopathy (ICD-9-CM code 289.1–289.3, 686, and 785.6), Hashimoto’s thyroiditis (ICD-9-CM code 245.2), Sjogren’s syndrome (ICD-9-CM code 710.2), irritable bowel syndrome (ICD-9-CM code 564.1), SLE (ICD-9-CM code 710.0), celiac disease (ICD-9-CM code 579.00, fibromyalgia (ICD-9-CM 729.1), and herpes zoster (ICD-9-CM code 053) anxiety disorders, insomnia, suicide, Crohn disease, ulcerative colitis, and renal disease, prior to the index date. These were evaluated as part of the analysis.
Anzeige
Statistical analysis
The descriptive statistics of CFS and the controls were reported, including demographic characteristics, comorbid diseases, and treatments received after the index date. The chi-square test was used to compare categorical variables, and Student’s t-test was used to compare continuous variables between the CFS cohort and the control cohort, as necessary. We used a logistic regression model to assess the CFS treatments the patients had received. The odds ratio (OR) and 95% confidence intervals (CIs) were calculated and then subsequently adjusted using covariates, which included age, sex, and comorbidities. Analyses were performed using SAS software (version 9.4 for Windows; SAS Institute, Cary, NC, USA). Values were considered statistically significant at p < 0.05.
Results
Of the 1,000,000 patients in the LHID2000 database, 6850 patients were diagnosed with CFS. Among these patients, 6306 patients were newly diagnosed with CFS during the study period. In total, 12,612 participants were enrolled, including 6306 CFS patients and 6306 non-CFS patients (Fig. 1). The demographic and clinical characteristics of the study participants are presented in Table 1. The participants were predominantly female and aged 35–64 years. The mean (standard deviation) age was 50.6 years in both groups. Patients in the CFS group most presented with the comorbidities of depression, anxiety disorder, insomnia, Crohn’s disease, ulcerative colitis, renal disease, type 2 diabetes, gout, dyslipidemia, rheumatoid arthritis, Sjogren syndrome, and herpes zoster.
Fig. 1
The selection process of the participants in the cohort study
Table 1
Demographic characteristics and comorbidities of patients newly diagnosed with chronic fatigue syndrome in Taiwan between 2000 and 2012 and of those in the control group
Variable
CFS cohort
Non-CFS cohort
P-value
(n = 6306)
(n = 6306)
Gender
> 0.99
Female
3339 (52.9)
3339 (52.9)
Male
2967 (47.1)
2967 (47.1)
Age at diagnosis of CFS
> 0.99
≤ 34
1350 (21.4)
1350 (21.4)
35–64
3485 (55.3)
3485 (55.3)
≥ 65
1471 (23.3)
1471 (23.3)
Age at diagnosis of CFS(mean, SD)†
50.6 (17.9)
50.6 (18.0)
0.80
Comorbidity
Depression
807 (12.8)
407 (6.45)
< 0.0001
Anxiety disorder
2038 (32.3)
1033 (16.4)
< 0.0001
Insomnia
2303 (36.5)
1106 (17.5)
< 0.0001
Suicide
19 (0.30)
12 (0.19)
0.20
Crohn's disease
255 (4.04)
121 (1.92)
< 0.0001
Ulcerative colitis
279 (4.42)
138 (2.19)
< 0.0001
Renal disease
585 (9.28)
427 (6.77)
< 0.0001
T1DM
78 (1.24)
68 (1.08)
0.40
T2DM
1473 (23.3)
1068 (16.9)
< 0.0001
Obesity
93 (1.47)
64 (1.01)
0.01
Gout
1196 (18.9)
702 (11.1)
< 0.0001
Dyslipidemia
2252 (35.7)
1356 (21.5)
< 0.0001
Malignancy
407 (6.45)
487 (7.72)
0.01
HIV
3 (0.05)
3 (0.05)
> 0.99
Rheumatoid arthritis
254 (4.03)
155 (2.46)
< 0.0001
Psoriasis
94 (1.49)
83 (1.32)
0.40
Ankylosing spondylitis
53 (0.84)
39 (0.62)
0.14
Lymphadenopathy
132 (2.09)
104 (1.65)
0.06
Hashimoto's thyroiditis
13 (0.21)
10 (0.16)
0.53
Sjogren's syndrome
110 (1.74)
71 (1.13)
0.003
Irritable bowel syndrome
886 (14.1)
423 (6.71)
< 0.0001
Fibromyalgia
4905 (77.8)
4914 (77.9)
0.85
SLE
4 (0.06)
9 (0.14)
0.16
Herpes zoster
341 (5.41)
234 (3.71)
< 0.0001
×
Table 2 lists the treatments received by both the patients with CFS and those without. With adjustments for sex, age, and comorbidities, patients with CFS had higher odds of receiving SSRIs (adjusted OR [aOR] = 1.70; 95% CI 1.48, 1.95), SNRIs (adjusted OR [aOR] = 1.52; 95% CI 1.20, 1.93), SARIs (aOR = 1.56; 95% CI 1.35, 1.78), TCAs (aOR = 1.37; 95% CI 1.07, 1.76), BZD (aOR = 1.70; 95% CI 1.57, 1.84), NDRI (aOR = 1.59; 95% CI 1.08, 2.36), Muscle relaxant (aOR = 1.52; 95% CI 1.24, 1.86) and Analgesic drug (aOR = 9.55; 95% CI 7.72, 11.81) than patients without CFS. Moreover, psychotherapy, including supportive individual psychotherapy (aOR = 1.28; 95% CI 1.09, 1.51), intensive individual psychotherapy (aOR = 2.73; 95% CI 1.47, 5.04), reeducative individual psychotherapy (aOR = 1.31; 95% CI 1.11, 1.56), stretching exercises (aOR = 1.26; 95% CI 1.10, 1.45), therapeutic exercise (aOR = 1.33; 95% CI 1.19, 1.47), and a brainwave examination for sleep disorders (20001C, 20002C; aOR = 1.40; 95% CI 1.25, 1.55) were frequently prescribed to patients with CFS. Figure 2 demonstrated the cumulative incidence calculated as the number of new patients who received nonpharmaceutical treatment divided by the total number of CFS patients who were at risk and multiple by 100. In 6850 CFS patients, the highest cumulative incidences of treatment were therapeutic exercise (14.95%), followed by brainwave examination for sleep disorders (11.58%) and stretching exercise (9.49%).
Table 2
Odds ratios for various treatments for patients with and without chronic fatigue syndrome
Variable
N
Control
CFS
Odds ratio
n
%
n
%
Crude (95% CI)
p-value
Adjusted (95% CI)
p-value
SSRI
2.33 (2.05,2.66)***
< 0.001
1.70 (1.48,1.95)***
< 0.001
No
11,471
5946
52
5525
48
Yes
1141
360
32
781
68
SNRI
2.22 (1.77,2.78)***
< 0.001
1.52 (1.20,1.93)***
< 0.001
No
12,260
6195
51
6065
49
Yes
352
111
32
241
68
SARI
2.21 (1.95,2.52)***
< 0.001
1.56 (1.35,1.78)***
< 0.001
No
11,451
5927
52
5524
48
Yes
1161
379
33
782
67
TCAs
1.79 (1.42,2.28)***
< 0.001
1.37 (1.07,1.76)*
0.01
No
12,310
6197
50
6113
50
Yes
302
109
36
193
64
BZD
2.13 (1.98,2.29)***
< 0.001
1.70 (1.57,1.84)***
< 0.001
No
5368
3260
61
2108
39
Yes
7244
3046
42
4198
58
NDRI
2.42 (1.67,3.51)***
< 0.001
1.59 (1.08,2.36)*
0.02
No
12,476
6266
50
6210
50
Yes
136
40
29
96
71
NaSSA
2.02 (1.57,2.59)***
< 0.001
1.28 (0.98,1.67)
0.08
No
12,331
6212
50
6119
50
Yes
281
94
33
187
67
Muscle relaxant
1.80 (1.49,2.19)***
< 0.001
1.52 (1.24,1.86)***
< 0.001
No
12,150
6139
51
6011
49
Yes
462
167
36
295
64
Analgesic drug
12.44 (10.12,15.3)***
< 0.001
9.55 (7.72,11.81)***
< 0.001
No
1173
1071
91
102
9
Yes
11,439
5235
46
6204
54
Supportive individual psychotherapy
1.90 (1.63,2.21)***
< 0.001
1.28 (1.09,1.51)**
0.003
No
11,837
6032
51
5805
49
Yes
775
274
35
501
65
Supportive group psychotherapy
2.29 (1.52,3.45)***
< 0.001
1.52 (0.99,2.35)
0.057
No
12,504
6273
50
6231
50
Yes
108
33
31
75
69
Intensive individual psychotherapy
3.95 (2.20,7.12)***
< 0.001
2.73 (1.47,5.04)**
0.001
No
12,543
6292
50
6251
50
Yes
69
14
20
55
80
Intensive group psychotherapy
2.13 (0.92,4.93)
0.078
1.57 (0.65,3.78)
0.318
No
12,587
6298
50
6289
50
Yes
25
8
32
17
68
Re-educative individual psychotherapy
2.01 (1.72,2.36)***
< 0.001
1.31 (1.11,1.56)**
0.002
No
11,881
6057
51
5824
49
Yes
731
249
34
482
66
Re-educative group psychotherapy
2.30 (1.37,3.84)**
0.002
1.49 (0.87,2.56)
0.149
No
12,543
6285
50
6258
50
Yes
69
21
30
48
70
Behavior modification assessment
No
12,612
6306
50
6306
50
Yes
0
0
0
0
0
Behavior modification planning
1.60 (1.02,2.54)*
0.043
1.15 (0.71,1.86)
0.582
No
12,534
6276
50
6258
50
Yes
78
30
38
48
62
Stretching exercise
1.44 (1.26,1.64)***
< 0.001
1.26 (1.10,1.45)***
< 0.001
No
11,600
5884
51
5716
49
Yes
1012
422
42
590
58
Therapeutic exercise
1.47 (1.33,1.63)***
< 0.001
1.33 (1.19,1.47)***
< 0.001
No
10,768
5535
51
5233
49
Yes
1844
771
42
1073
58
Breathing exercise
1.04 (0.82,1.32)
0.758
0.92 (0.71,1.18)
0.506
No
12,343
6174
50
6169
50
Yes
269
132
49
137
51
Reconditioning exercise
1.30 (0.94,1.79)
0.108
1.19 (0.85,1.67)
0.310
No
12,456
6238
50
6218
50
Yes
156
68
44
88
56
Multiple physical examinations of sleep
1.48 (1.10,2.00)*
0.011
1.07 (0.78,1.47)
0.676
No
12,434
6234
50
6200
50
Yes
178
72
40
106
60
Brainwave examination, sleep or wakefulness
1.60 (1.44,1.77)***
< 0.001
1.40 (1.25,1.55)***
< 0.001
No
10,825
5590
52
5235
48
Yes
1787
716
40
1071
60
Brainwave examination for sleep disorders
No
12,612
6306
50
6306
50
Yes
0
0
0
0
0
CFS: chronic fatigue syndrome; N: total number of subjects the subgroups; n: number of subjects; CI: confidence interval; SSRI: selective serotonin receptor inhibitors; SNRI: serotonin norepinephrine Reuptake Inhibitors; SARI: serotonin antagonist and reuptake inhibitors; TCAs: tricyclic antidepressant; MAOi: Monoamine oxidase inhibitors; BZD: benzodiazepine; *P < .05, **P < .01, ***P < .001
Fig. 2
Cumulative incidences of different nonpharmaceutical treatment among the CFS subpopulations
×
The stratification of treatments for patients with CFS in terms of depression, anxiety disorders, and insomnia is presented in Table 3. For patients with depression, those with CFS were more likely to receive SSRIs, SNRIs, SARIs, BZD, analgesic drugs, reeducative individual psychotherapy and therapeutic exercise. SSRIs, SNRIs, SARIs, BZD, NDRI, analgesic drugs, muscle relaxants, reeducative individual psychotherapy stretching exercise and therapeutic exercise were commonly prescribed for patients with CFS identified with an anxiety disorder. In the subgroup of patients with insomnia, SSRIs, SNRIs, SARIs, BZD, analgesic drugs, reeducative individual psychotherapy and therapeutic exercise were most prescribed to patients with CFS.
Table 3
The odd ratios of treatments for patients with and without chronic fatigue syndrome in difference subgroup of comorbidities
As presented in Table 4, patients with CFS were more likely to receive SSRIs, BZD and analgesic drugs in each age group. The odds of patients with CFS aged 35–64 and ≥ 65 receiving SARIs and muscle relaxant treatments were higher than the odds of those without CFS. For participants aged 35–64 years, reeducative individual psychotherapy was also frequently received by patients with CFS. Female and male patients with CFS were equally likely to be treated with SSRIs, SNRIs, SARIs, BZD, muscle relaxants, analgesic drugs, reeducative individual psychotherapy, intensive individual psychotherapy and therapeutic exercise, TCAs was higher prescribed to female and NDRI was higher used in male, as presented in Table 5.
Table 4
The odd ratios of treatments for patients with and without chronic fatigue syndrome in difference subgroup of age
Our nationwide population-based study revealed that patients with CFS experienced more comorbidities, such as psychiatric problems (depression, anxiety disorders, and insomnia), autoimmune diseases (Crohn disease, ulcerative colitis, rheumatoid arthritis, and Sjogren syndrome), type 2 diabetes, renal diseases, and malignancy, than the participants without CFS. In addition, we found that the use of SSRIs, SARIs, SNRIs, TCAs, NDRI, BZD, muscle relaxants, analgesic drugs, psychotherapies and exercise therapies were higher in the CFS cohort. This finding is consistent with the general treatment for CFS [14]. Notably, brainwave examination is not a standard examination method for diagnosing CFS, but it was regularly used by clinicians in our study.
The etiology of CFS remains unknown. Emerging research suggests CFS is an autoimmune disease, with evidence of dysregulation of the immune and autonomic nervous systems as well as metabolic disturbances, triggered particularly by infection with stress [15]. Patients with CFS have been identified as having increased levels of autoantibodies against ß2-adrenergic receptors and M3 acetylcholine receptors [16]. The hypothalamic–pituitary–adrenal (HPA) axis maintains homeostasis through a self-regulating feedback system that helps to manage stress [17, 18], and abnormalities in the HPA axis are believed to be a feature of CFS [19]. In addition, we previously reported that psoriasis and inflammatory bowel disease significantly increased the risk of CFS [10, 11]. In future studies, the aspects of CFS linked to autoimmune diseases should be clarified.
In recent 2 years during COVID-19 pandemic, many studies indicated that some COVID-19 patients had persistent clinical signs and symptoms including fatigue, breathlessness, and cognitive dysfunction after recovering from initial illness. This condition named Post COVID-19 Syndrome or long COVID. Pathological inflammation with immune dysfunction was a one of the underlying multifactorial mechanism of long COVID, which was similar to CFS [20‐22]. Various autoantibodies were found in 10–50% of patients with COVID-19 [23]. These autoantibodies and increased levels of pro-inflammatory markers contributed to the disease severity and inflammation-related symptoms such as fatigue and joint pain [22, 24]. The treatments of CFS were believed to have a potential effect of relieving fatigue in long COVID cases [22, 25]. Future studies should be conducted to determine the underlying mechanism and treatments between CFS and long COVID.
Anzeige
Our comparison of patients with CFS with those without demonstrated that the use of SSRIs, SNRIs, SARIs and BZD was higher in the CFS cohort after adjustments for age, sex, and comorbidities (Table 2), especially in those with psychiatric problems (depression, anxiety disorders, and insomnia; Table 3). However, a subclassification analysis of age and sex established no significant differences between the two groups (Tables 4 and 5). Patients with CFS have been reported to have clinical depression and anxiety [26], and several pathophysiologies related to depression have been reported, such as inflammation with elevated cytokine levels (e.g., interleukin [IL]-1, tumor necrosis factor alpha [TNF-α]), increased oxidative stress, and decreased neurotrophic factors and brain neurotransmitters [27]. Serotonin (or 5-hydroxytryptamine 1A [5-HT1A]), a monoamine neurotransmitter, has been discovered to be linked to mood, behavior, sleep cycles, and appetite [28]. One study indicated that the number of brain 5-HT1A receptors was decreased in patients with CFS, with the decrease particularly marked in the bilateral hippocampus [29]. Furthermore, changes in the HPA axis in chronic stress were reported to be associated with the serotonin system and abnormal adrenocortical activity and were observed in patients with CFS [30]. One study indicated that patients with CFS prescribed SSRIs had a faster rate of recovery and experienced a greater reduction in fatigue levels than untreated patients [31]. However, few clinical trials have been conducted on CFS treatments, although the use of SSRIs for fibromyalgia, especially for patients with depression, may be advantageous for CFS [32]. Bupropion, a norepinephrine-dopamine reuptake inhibitor (NDRI), was reported to improve hypersomnia and fatigue significantly in the patients with major depressive disorder compared with the placebo-group [33]. Unrefreshing sleep is one feature of CFS, Cognitive-behavioral therapy for insomnia (CBT-I) and sleep hygiene education should be applied whenever possible [34]. Experienced clinicians believed that low-dose TCAs and BZD may also be useful for sleep. However, monitoring the adverse effects including drowsiness upon awakening must be considered.
Treatments for pain symptoms, including muscle relaxants and analgesic drugs, were more common among the CFS cohort (Table 2), but no significant difference in psychiatric comorbidities, age, or sex was identified in the subclassification analysis (Tables 3, 4, and 5). Chronic pain in the muscles, joints, and subcutaneous tissues was a common presenting symptom in patients with CFS. The potential contributing mechanisms may be oxidative and nitrosative stress, low-grade inflammation, and impaired heat shock protein production [35]. Another hypothesis concerning muscle fatigue is that it results from the overutilization of the lactate dehydrogenase pathway and slowed acid clearance after exercise [36]. The mainstream management of pain in CFS is similar to that for fibromyalgia. Pain can be treated with NSAIDs or acetaminophen. Pregabalin or gabapentin are helpful for neuropathic and fibromyalgia pain [37]; however, clinicians should be aware of the adverse effects of this treatment on cognitive dysfunction and weight gain. One systematic review indicated that cyclobenzaprine was more effective for back pain [38] but was associated with the side effects of drowsiness, dizziness, and dry mouth. Nonpharmacologic interventions for pain vary, and useful modalities include meditation, warm baths, massage, stretching, acupuncture, hydrotherapy, chiropractic, yoga, tai chi, and transcutaneous electrical nerve stimulation [14, 39].
According to the information released by NHIRD and clinical experiences, the supportive individual psychotherapy is performed by various professional members in psychiatric team under the psychiatrists’ guidance. The re-educative individual psychotherapy is mainly performed by psychotherapists and the intensive individual psychotherapy is administered by psychiatrists. Our results found the application of all psychotherapy was higher in the CFS cohort since those with psychiatric problems are mostly referred to psychotherapists for re-educative individual psychotherapy. However, the group psychotherapy is not a first choice for clinicians in Taiwan. In the age and sex subclassification analysis, psychotherapy was not prescribed significantly more frequently to young aged (below or equal to 34 y/o) patients. With regard to nonpharmaceutical options, cognitive behavioral therapy (CBT), a psychotherapy, has been prescribed to patients with CFS. CBT includes relaxation exercises, the development of coping mechanisms, and stress management, and it is an effective treatment for depression and anxiety and eating and panic disorders [40]. One randomized trial reported that CBT and graded exercise therapy (GET) were safe for CFS and effective at improving fatigue and functional impairment [41, 42]. A 16 week standard individual CBT has been shown to be beneficial in physical function and fatigue [43]. Furthermore, CBT is the most cost-effective treatment option for CFS [44]. Although CBT is often used with GET, the program should be discussed with patients to ensure their compliance.
Brainwave examination was also significantly more frequently prescribed in the CFS cohort (OR = 1.40; Table 2), regardless of whether the participant had depression, an anxiety disorder, or insomnia (Table 3). On the other hand, polysomnography (PSG), including brainwave examination (EEG), eye movements (EOG), muscle activity or skeletal muscle activation (EMG), and heart rhythm (ECG) records certain body functions during sleeping, Nonrestorative sleep is a key feature of CFS and is defined as the subjective experience that sleep has not been sufficiently refreshing or restorative [45, 46], resulting in increased daytime drowsiness, mental fatigue, and neurocognitive impairment [47]. Primary sleep disorders (PSDs), including primary insomnia, obstructive sleep apnea, periodic limb movement disorder, and narcolepsy, occur in approximately 18% of patients with CFS [48]. PSG is a key tool for detecting these disorders. Patients with more severe symptoms should be routinely screened for PSDs with appropriate questionnaires, a semistructured history interview, and PSG [49].
Anzeige
Some emerging management strategies for CFS have been proposed in recent years. The fact that drugs targeting immune responses or impaired autoregulation of blood flow was indicated to be effectual in CFS [50]. We previously discovered that the increased risk of CFS among patients with psoriasis was attenuated by immunomodulatory drugs [11]. In addition, a small placebo-controlled and open study mentioned that rituximab achieved sustained clinical responses in patients with CFS [51], and a clinical trial demonstrated that rintatolimod, a restricted toll-like receptor 3 agonist, achieved significant improvements in patients with CFS [52]. Furthermore, increased levels of several cytokines, including IL-1 and TNF-α, have been positively correlated with fatigue [53]. These findings provide insight into treating CFS through immune pathways. Another emerging treatment of CFS is dietary intervention, with one systemic review indicating that nicotinamide adenine dinucleotide hydride, coenzyme Q10, and probiotic supplements relieved CFS symptoms [54]. These potential mechanisms contribute by increasing adenosine triphosphate production and improving gut microbiota. Aripiprazole was reported to relieve the symptoms of CFS including fatigue and unrefreshing sleep effectively [55]. Biofeedback therapy has also demonstrated benefits in the treatment of CFS. Compared with GET, heart rate variability biofeedback therapy has improved quality of life in cases of mental health disorders, including depression, potentially through the enhancement of self-efficacy and self-control [56].
Our study has some limitations. First, the severity of CFS and efficacy of the treatment were not evaluated in the study because of limited information available in the NHIRD. Second, some nonpharmaceutical treatments, such as meditation and massage, were not included in our study because they were not included in the database. Third, patients’ personal information and family histories, such as symptoms, occupation, and laboratory data, were not available because of the anonymity of the NHIRD. Fourth, incorrect coding and diagnoses in the database may have resulted in bias in the data analysis; however, such errors may result in considerable penalties for physicians, and hence, they are unlikely. Moreover, data on 99.9% of Taiwan’s population are contained in the NHIRD, making the database a robust source of data, the reliability and validity of which have been reported previously [57]. Consequently, the diagnoses and codes should be reliable in our study.
Conclusion
In our nationwide population-based cohort study, the use of SSRIs, SARIs, SNRIs, TCAs, NDRI, BZD, muscle relaxants, analgesic drugs, psychotherapies and exercise therapies were prescribed significantly more frequently in the CFS cohort than in the control group. Previous studies have reported these treatments to be effective at relieving the symptoms of CFS and useful for managing related comorbidities.
Acknowledgements
We would like to extend acknowledgment to Dr. Jung-Nien Lai’s and Miss. Yu-Chi Yang's material support, and the listed institutes and Department of Medical Research at Mackay Memorial Hospital, and Mackay Medical College for funding support.
Anzeige
Declarations
Ethics approval and consent to participate
The authors assert that all procedures contributing to this work comply with the ethical standards of the relevant national and institutional committees on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008. This study was approved by the Research Ethics Committee of the China Medical University Hospital (CMUH-104-REC2-115) and the Institutional Review Board of Mackay Memorial Hospital (16MMHIS074).
Consent for publication
The authors agree with the publication of this paper.
Competing interests
The authors declare that there is no conflict of interest regarding the publication of this paper.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.
Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.
Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.
Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.
Update Innere Medizin
Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.
